TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 010196 AND 011296—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Shared Technologies, Inc., Jeffrey J. Steiner, Fairchild Industries, Inc	96–0664	01/05/96
Jeffrey J. Steiner, Shared Technologies Inc., Shared Technologies Inc	96–0665	01/05/96
National Gaming Corp., Forte Plc, Forte Hotels, Inc	96–0706	01/05/96
Paul F. Wallace, Forte Plc, Forte Hotels, Inc	96–0707	01/05/96
USIF, Real Estate, Forte Plc, Forte Hotels, Inc	96–0708	01/05/96
Texaco Inc., Royal Dutch Petroleum Company, Shell Western E&P, Inc	96–0533	01/11/96
Alco Standard Corporation, Mark E. Hawn, Atlanta Legal Copies, Inc	96–0627	01/11/96
Everett R. Dobson Irrevocable Family Trust, Telephone and Data Systems, Inc. Voting Trust, Telephone and Data Systems, Inc. Voting Trust	96–0655	01/11/96
Jeffrey J. Steiner, Banner Aeorspace, Inc., Banner Aerospace, Inc	96–0675	01/11/96
Block Drug Company, Inc., The Proctor & Gamble Company, The Proctor & Gamble Company	96–0677	01/11/96
The Atlantic Foundation, Envoy Corporation, Envoy Corporation	96–0696	01/11/96
Estate of Charles A. Sammons, NACOLAH Holding Corporation, NACOLAH Holding Corporation	96–0700	01/11/96
HFS, Incorporated, Forte plc, Forte Hotels, Inc	96–0705	01/11/96
LCI International, Inc., Ronald H. Vanderpol, Teledial America, Inc	96–0712	01/11/96
Brooks Fiber Properties, Inc., Ronald H. VanderPol, City Signal, Inc	96–0720	01/11/96
Ronald H. VanderPol, Brooks Fiber Properties, Inc., Brooks Fiber Properties, Inc	96–0721	01/11/96
The Chase Manhattan Corporation, James I. Swenson, Swenson Family Trust, revocable trust, Details, Inc	96–0723	01/11/96
Champion International Corporation, Toufic Aboukhater, Lake Superior Land Company	96–0731	01/11/96
Vestar Equity Partners, L.P., Acadia Partners, L.P., Pinnacle Automation, Inc	96–0736	01/11/96
Delco Remy International, Inc., Beurt R. SerVaas, Power Investments, Inc	96–0742	01/11/96
Yamaha Motor Co., Ltd., Ronald O. Perelman, Skeeter Products, Inc	96–0744	01/11/96

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Renee A. Horton, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC. 20580 (202) 326–3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 96–1043 Filed 1–23–96; 8:45 am]

BILLING CODE 6570–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CRADA 96–001]

National Institute for Occupational Safety and Health Cooperative Research and Development Agreement

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), announces the opportunity for potential collaborators to enter into a Cooperative Research and Development Agreement (CRADA) to develop a direct reading immunoassay device for monitoring human urinary metabolites of the herbicide, alachlor. Humans metabolize alachlor in such a way as to produce a set of chemically altered compounds (metabolites) that are more easily excreted, primarily in urine. By determining the level of these metabolites in urine of workers who are at risk for exposure to alachlor, an assessment of exposure can be made. The device that CDC wants to have developed would allow rapid and easy determination of urinary metabolite levels, thus allowing intervention procedures to be implemented.

It is anticipated that all inventions which may arise from the CRADA will be jointly owned. The collaborator with whom the CRADA is made will have an option to negotiate an exclusive or non-exclusive royalty-bearing license. The CRADA will be executed for a 2-year period with the possibility of renewal for another 2-year period.

Because CRADAs are designed to facilitate the development of scientific and technological knowledge into useful, marketable products, much freedom is given to Federal agencies in implementing collaborative research. The CDC may accept staff, facilities, equipment, supplies, and money from the other participants in a CRADA; CDC may provide staff, facilities, equipment and supplies to the project. There is a single restriction in this exchange: CDC MAY NOT PROVIDE FUNDS to the other participants in a CRADA.

This opportunity is available until February 23, 1996. Respondents may be provided a longer period of time to furnish additional information if CDC finds this necessary.

FOR FURTHER INFORMATION:

Technical: R. DeLon Hull, Ph.D. or J. Patrick Mastin, Ph.D., Division of Biomedical and Behavioral Sciences, National Institute for Occupational Safety and Health, CDC, 4676 Columbia Parkway, Mailstop C–26, Cincinnati, Ohio 45226, Telephone 513–533–8122 and 513–533–8399, Fax 513–533–8510.

Business: Theodore F. Schoenborn, Technology Transfer Coordinator, National Institute for Occupational Safety and Health, CDC, 4676 Columbia Parkway, Mailstop R–2, Cincinnati, Ohio 45226, Telephone 513–841–4305, Fax 513–841–4500.

SUPPLEMENTARY INFORMATION: The direct reading device should be similar to home pregnancy test kits and suitable for use by the worker or a local health care professional. For instance a test strip made of an absorbent material such as chromatography paper would be held in the urine stream or dipped in a sample of urine and the urine allowed to wick up the strip. The presence and approximate concentration of the metabolite would be visualized as, for instance, a color change (as with pH test paper) or the appearance of a color band at a height indicative of the concentration of the metabolite. The concentration of metabolite could then be estimated, for example, from a gradient scale imprinted on the device or by comparison to a visual standard. Urine from herbicide applicators being screened during NIOSH field studies will be used to test the strips as they are being developed.

The device should meet the following requirements:

Requires no special expertise to use, so that workers or their local health professionals can use the device.

Be immunoassay-based, in order to get sufficient sensitivity and selectivity.

Be self-contained, i.e., does not require any instrumentation for analysis.

Be produced easily and inexpensively and be readily available to workers.

Applicants will be judged according to the following criteria:

1. Adequacy and technical capabilities to develop the desired technologies and product;

2. Ability to develop, produce, market, and support the device; and

3. Ability to complete the CRADA in a timely fashion.

This CRADA is proposed and implemented under the 1986 Federal Technology Transfer Act: Public Law 99–502.

The response must be made to: Theodore F. Schoenborn, Technology Transfer Coordinator, National Institute for Occupational Safety and Health, CDC, 4676 Columbia Parkway, Mailstop R–2, Cincinnati, Ohio 45226 Telephone 513–841–4305, Fax 513–841–4500.

Dated: January 17, 1996.

Linda Rosenstock,

Director, National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–950 Filed 1–23–96; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

[Docket No. 95D–0166]

Quality Assurance Program Audits and Inspections; Compliance Policy Guide; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a revised Compliance Policy Guide (CPG) 7151.02 entitled ''FDA Access to Results of Quality Assurance Program Audits and Inspections.'' This revised CPG provides general policy and guidance to FDA field and headquarters staff (engaged in the inspection and investigation of any regulated entity) regarding routine access to review reports or copying of records that result from the entity's audits and inspections of a written quality assurance program.

ADDRESSES: CPG 7151.02 is available for public examination in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Tom M. Chin, Office of Enforcement (HFC–230), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–0410.

SUPPLEMENTARY INFORMATION: FDA has revised CPG 7151.02 entitled ''FDA Access to Results of Quality Assurance Program Audits and Inspections.'' This CPG was revised to provide general policy and clearer guidance to FDA field and headquarters staff (engaged in the inspection and investigation of any regulated entity) regarding routine access to review reports or copying of records that result from the entity's audits and inspections of a written quality assurance program.

The statements made in CPG 7151.02 are not intended to bind the courts, the public, or FDA, or to create or confer any rights, privileges, immunities, or benefits on or for any private person, but are intended merely for internal FDA guidance.

Dated: January 3, 1996.

Gary Dykstra

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 96–940 Filed 1–23–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95D–0386]

Guidance for Industry; Content and Format of Investigational New Drug Applications (IND's) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ''Guidance for Industry; Content and Format of Investigational New Drug Applications (IND's) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products.'' The guidance clarifies data requirement issues related to the initial entry of an unapproved drug into human studies in the United States. The guidance is intended to expedite the entry of new drugs into clinical studies by eliminating ambiguities in IND requirements and by decreasing inconsistencies in IND reviews.

DATES: Written comments on the guidance may be submitted at any time.

ADDRESSES: Submit written requests for single copies of the guidance entitled ''Guidance for Industry; Content and Format of Investigational New Drug Applications (IND's) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products'' to the Consumer Affairs Branch (formerly the CDER Executive Secretariat Staff), Center for Drug Evaluation and Research (HFD–210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, or the Congressional and Consumer Affairs Branch, Center for Biologics Evaluation and Research (HFM–12), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–594–1800 or 800–835–4709. Send two self-addressed adhesive labels to assist the offices in processing your requests. A copy of the guidance document is also available from CDER's FAX On Demand. To obtain a copy from FAX On Demand, call 1–800–342–2722 or locally 301–827–0577. An electronic version of the guidance document is also available via Internet. Requesting persons should connect to the CDER file transfer protocol (FTP) server (CDVS2.CDER.FDA.GOV) using the FTP protocol. The guidance is available in WordPerfect versions 5.2 and 6.0. Submit written comments on the guidance to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Murray M. Lumpkin, Center for Drug Evaluation and Research (HFD–2), Food and Drug Administration, 1451 Rockville Pike, Rockville, MD 20852, 301–594–6740, or Rebecca Devine, Center for Biologics Evaluation and Research (HFM–10), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0373.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a guidance entitled ''Guidance for Industry; Content and Format of Investigational New Drug Applications (IND's) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products.'' Any use in humans in the United States of a drug product not